Treatment of Low Back Pain with Botulinum Neurotoxins

Pain Practice

Volumn 4, Issue , 2004, Pages S47-S53

  Jabbari, Bahman ^a   Ney, John ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO;

ANTIBODY PRODUCTION; ANTINOCICEPTION; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; LOW BACK PAIN; MALAISE; MUSCLE WEAKNESS; NONHUMAN; PAIN ASSESSMENT; QUESTIONNAIRE;

EID: 18844453226     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2004.04014.x     Document Type: Article

References (54)

1. Walker BF. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord. 2000;13: 205-217.
2. Hoy D, Toole MJ, Morgan D, Morgan C. Low back pain in rural Tibet. Lancet. 2003;361: 225-226.
3. Omokhodion FO. Low back pain in a rural community in South West Nigeria. West Afr J Med. 2002;21: 87-90.
4. Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001;344: 363-370.
5. Deyo RA. Low-back pain. Sci Am. 1998;279: 48-53.
6. Guo HR, Tanaka S, Cameron LL, et al. Back pain among workers in the United States: national estimates and workers at high risk. Am J Ind Med. 1995;28: 591-602.
7. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268: 760-765.
8. Boden SD, Davis DO, Dina TS, Patronas NJ, Wiesel SW. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation. J Bone Joint Surg Am. 1990;72: 403-408.
9. Bigos SJ, Davis GE. Scientific application of sports medicine principles for acute low back problems. The Agency for Health Care Policy and Research Low Back Guideline Panel (AHCPR, Guideline #14). J Orthop Sports Phys Ther. 1996;24: 192-207.
10. Van Tulder MW, Scholten RJPM, Koes BW, Deyo RA. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 2000;25: 2501-2513.
11. Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Review (The Cochrane Library). 2003;Issue 3: 1-39.
12. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine. 1998;23: 2591-2600.
13. Atkinson JH, Slater MA, Williams RA, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76: 287-296.
14. Weber H. Lumbar disc herniation. A controlled, prospective study with ten years of observation. Spine. 1983;8: 131-140.
15. Gibson JN, Grant IC, Waddell G. The Cochrane review of surgery for lumbar disc prolapse and degenerative lumbar spondylosis. Spine. 1999;24: 1820-1832.
16. Rosenow DE. Does neural blockade and other neurosurgical modalities offer a durable pain relief for spinal disorders? Best Pract Res Clin Rheumatol. 2002;16: 155-164.
17. Van Kleef M, Barendse GA, Kessels A, Voets HM, Weber WE, De Lange S. Randomized trial of radiofrequency lumbar facet denervation for chronic low back pain. Spine. 1999;24: 1937-1942.
18. Rozenberg S, Dubourg G, Khalifa P, Paolozzi L, Maheu E, Ravaud P. Efficacy of epidural steroids in low back pain and sciatica. A critical appraisal by a French Task Force of randomized trials. Critical Analysis Group of the French Society for Rheumatology. Rev Rhum Engl Ed. 1999;66: 79-85.
19. Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of epidural steroid injections for low-back pain and sciatica: a systematic review of randomized clinical trials. Pain. 1995;63: 279-288.
20. Hagen KB, Hilde G, Jamtvedt G, Winnem MF. The Cochrane review of bed rest for acute low back pain and sciatica. Spine. 2000;25: 2932-2939.
21. Van Tulder MW, Cherkin DC, Berman B, Lao L, Koes BW. The effectiveness of acupuncture in the management of acute and chronic low back pain. A systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine. 1999;24: 1113-1123.
22. Leibing E, Leonhardt U, Koster G, et al. Acupuncture treatment of chronic low-back pain-a randomized, blinded, placebo-controlled trial with 9-month follow-up. Pain. 2002;96: 189-196.
23. Brosseau L, Milne S, Robinson V, et al. Efficacy of the transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a meta-analysis. Spine. 2002;27: 596-603.
24. Preyde M. Effectiveness of massage therapy for subacute low-back pain: a randomized controlled trial. CMAJ. 2000;162: 1815-1820.
25. Cherkin DC, Deyo RA, Battie M, Street J, Barlow W. A comparison of physical therapy, chiropractic manipulation, and provision of an educational booklet for the treatment of patients with low back pain. N Engl J Med. 1998;339: 1021-1029.
26. Cherkin DC, Deyo RA, Street JH, Barlow W. Predicting poor outcomes for back pain seen in primary care using patients' own criteria. Spine. 1996;21: 2900-2907.
27. Croft PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman AJ. Outcome of low back pain in general practice: a prospective study. BMJ. 1998;316: 1356-1359.
28. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc. 1981;79: 734-770.
29. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103: 347-350.
30. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2: 245-247.
31. Tsui JK, Fross RD, Calne S, Calne DB. Local treatment of spasmodic torticollis with botulinum toxin. Can J Neurol Sci. 1987;14: 533-535.
32. Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40: 277-280.
33. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8: 559-565.
34. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry. 1996;61: 30-35.
35. Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol. 1997;4(suppl 2):S71-S73.
36. Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res. 1999;4: 183-186.
37. Opida CL. Open-label study of myobloc (botulinum toxin type b) in the treatment of patients with transformed migraine headaches [poster 639]. Available at: http://www.ampainsoc.org/abstract/2002/data/1280. Accessed January 31, 2004.
38. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123: 669-676.
39. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol. 2000;27: 481-484.
40. Smith HS, Audette J, Royal MA. Botulinum toxin in pain management of soft tissue syndromes. Clin J Pain. 2002;18(6 suppl):S147-S154.
41. Opida CL. Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with chronic low back pain. Naunyn Schmiedebergs Arch Pharmacol. 2002;365: PR33.
42. ®), administered using a novel injection technique, for the treatment of myofascial pain. American Journal of Pain Management. 2000;10: 108-112.
43. Royal MA, Gunyea I, Bhakta B, Movva V, Ward S, Jenson M. Botulinum toxin type A in the treatment of refractory myofacial pain [abstract P05.091]. Neurology. 2001;56(suppl 3):A350.
44. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain. 2002;18(6 suppl):S155-S162.
45. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56: 1290-1293.
46. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain. 1994;56: 217-226.
47. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980;66: 271-273.
48. Jabbari B, Ney J, Sichani A, et al. Treatment of chronic low back pain with Botulinum Toxin A: a prospective study of 60 patients. Spine. 2003 (In press).
49. Patocka J, Splino M. Botulinum toxin: from poison to medicinal agent. The ASA Newsletter. 2002;02-1: 14-23.
50. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3: 333-335.
51. Kedlaya D. Botulinum toxin: overview. Available at: http://www.emedicine.com/pmr/topic216.htm. Accessed June 15, 2003.
52. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9: 213-217.
53. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45: 1743-1746.
54. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002;18(6 suppl):S133-S141.